N-BOC-4-(2-乙氧羰基乙酰基)哌啶 | 479630-08-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-BOC-4-(2-乙氧羰基乙酰基)哌啶
• 中文别名: 叔丁基4-(3-乙氧基-3-氧代丙酰)哌啶-1-甲酸酯；1-Boc-B-氧代-4-哌啶丙酸乙酯；1-[(1,1-二甲基乙氧基)羰基]-beta-氧代-4-哌啶丙酸乙酯；3-氧代-3-(1-Boc-4-哌啶基)丙酸乙酯；4-(2-乙氧羰基乙酰基)哌啶羧酸叔丁酯
• 英文名称: 4-(2-ethoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(3-ethoxy-3-oxopropanoyl)piperidine-1-carboxylate
• CAS: 479630-08-5
• 化学式: C₁₅H₂₅NO₅
• mdl: MFCD04115569
• 分子量: 299.367
• InChiKey: CWTULLANCDLMGK-UHFFFAOYSA-N

物化性质

• 沸点：
  386.1±32.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-(3-ethoxy-3-oxopropanoyl)piperidine-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-(3-ethoxy-3-oxopropanoyl)piperidine-1-carboxylate
CAS number: 479630-08-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H25NO5
Molecular weight: 299.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

N-BOC-4-(2-乙氧羰基乙酰基)哌啶是一种哌啶衍生物，作为重要的有机合成中间体，它在医药和科研领域展现出广泛的应用前景。

反应信息

• 作为反应物：
  描述：

  N-BOC-4-(2-乙氧羰基乙酰基)哌啶 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 20.0h， 以94%的产率得到4-乙酰基哌啶-1-甲酸叔丁酯
  参考文献：
  名称：

  Meso-piperidine calix[4]pyrrole: synthesis, structure and ion binding studies

  摘要：

  We report the synthesis, structure and preliminary solution phase ion binding properties of the calix[4] pyrrole 3a-c. Calix[4]pyrrole 3a and 3b, the first to be prepared via one-pot reaction, were obtained by reacting the ketone 7 with pyrrole in the presence of an acid catalyst. On the basis of H-1 NMR spectroscopic analyses and the titrations of UV spectrophotometry, it was concluded that compound 3a possesses significantly enhanced selectivity for fluoride anion in chloroform, and formes 1:1 (ligand: anion) complexes with fluoride and chloride anions. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.08.032
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸甲酯 在 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 28.0h， 生成 N-BOC-4-(2-乙氧羰基乙酰基)哌啶
  参考文献：
  名称：

  PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AND USE OF ANTI-TUMOR THEREOF

  摘要：

  本发明涉及一种通式1的吡唑并[1,5-a]嘧啶衍生物及其药用可接受的盐。本发明还涉及在制备抗肿瘤药物时使用通式1的化合物。

  公开号：

  US20160102095A1
• 作为试剂：
  描述：

  4-乙酰基哌啶-1-甲酸叔丁酯 、 碳酸二乙酯 在 N-BOC-4-(2-乙氧羰基乙酰基)哌啶 、 crude product 、 silica gel 、 methanol-dichloromethane 作用下， 以to yield 1.16 g (41%) of tert-butyl 4-(3-ethoxy-3-oxopropanoyl)piperidine-1-carboxylate as a colorless oil的产率得到N-BOC-4-(2-乙氧羰基乙酰基)哌啶
  参考文献：
  名称：

  PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF

  摘要：

  一种式为A的吡唑并[5,1-c][1,2,4]三嗪化合物及其药学上可接受的盐。本发明的多取代吡唑并[5,1-c][1,2,4]三嗪化合物选择性地抑制B-Raf激酶活性，可用于治疗由B-Raf激酶介导的疾病。

  公开号：

  US20090082354A1

文献信息

• [EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005090333A1

  公开（公告）日：2005-09-29

  Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开的化合物式(I)，可以抑制与炎症过程有关的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理状况，如慢性炎症性疾病。还公开了制备这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATIONS DE DÉRIVÉS DE PYRIMIDINONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018055402A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

  本发明涉及式(I)的化合物，以及其盐和溶剂合物，其作为细胞分裂周期7（Cdc7）激酶酶活性的抑制剂：（式(I)）其中X，R1，R2和n如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及Cdc7激酶活性的疾病或病况中的用途。
• [EN] INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS<br/>[FR] INDAZOLOPYRIMIDINONES COMME INHIBITEURS DE LA FIBRINOLYSE
  申请人：BAYER PHARMA AG

  公开号：WO2016173948A1

  公开（公告）日：2016-11-03

  The present application relates to novel substituted indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代吲唑吡咯嘧啶酮，其制备方法，以及用于治疗和/或预防疾病的化合物，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者急性和复发性出血的方法，其中出血与从重经期出血、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：GUO YUNHANG

  公开号：WO2014173289A1

  公开（公告）日：2014-10-30

  The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

  该发明涉及式(I)的融合杂环化合物及其盐、组合物以及使用方法。具体地，在此披露了某些融合杂环化合物，可用于抑制蛋白激酶，包括布鲁顿酪氨酸激酶（Btk），并用于治疗由此介导的疾病。